Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
Top Cited Papers
- 28 January 2021
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 384 (4), 325-334
- https://doi.org/10.1056/nejmoa2008470
Abstract
No therapies are currently approved for the treatment of pulmonary hypertension in patients with interstitial lung disease. The safety and efficacy of inhaled treprostinil for patients with this condition are unclear. We enrolled patients with interstitial lung disease and pulmonary hypertension (documented by right heart catheterization) in a multicenter, randomized, double-blind, placebo-controlled, 16-week trial. Patients were assigned in a 1:1 ratio to receive inhaled treprostinil, administered by means of an ultrasonic, pulsed-delivery nebulizer in up to 12 breaths (total, 72 μg) four times daily, or placebo. The primary efficacy end point was the difference between the two groups in the change in peak 6-minute walk distance from baseline to week 16. Secondary end points included the change in N-terminal pro–B-type natriuretic peptide (NT-proBNP) level at week 16 and the time to clinical worsening. A total of 326 patients underwent randomization, with 163 assigned to inhaled treprostinil and 163 to placebo. Baseline characteristics were similar in the two groups. At week 16, the least-squares mean difference between the treprostinil group and the placebo group in the change from baseline in the 6-minute walk distance was 31.12 m (95% confidence interval [CI], 16.85 to 45.39; P<0.001). There was a reduction of 15% in NT-proBNP levels from baseline with inhaled treprostinil as compared with an increase of 46% with placebo (treatment ratio, 0.58; 95% CI, 0.47 to 0.72; P<0.001). Clinical worsening occurred in 37 patients (22.7%) in the treprostinil group as compared with 54 patients (33.1%) in the placebo group (hazard ratio, 0.61; 95% CI, 0.40 to 0.92; P=0.04 by the log-rank test). The most frequently reported adverse events were cough, headache, dyspnea, dizziness, nausea, fatigue, and diarrhea. In patients with pulmonary hypertension due to interstitial lung disease, inhaled treprostinil improved exercise capacity from baseline, assessed with the use of a 6-minute walk test, as compared with placebo. (Funded by United Therapeutics; INCREASE ClinicalTrials.gov number, NCT02630316.)Keywords
Funding Information
- United Therapeutics Corporation
This publication has 16 references indexed in Scilit:
- Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosisRespiratory Medicine, 2015
- Use of Pulmonary Arterial Hypertension–Approved Therapy in the Treatment of Non–Group 1 Pulmonary Hypertension at US Referral CentersPulmonary Circulation, 2015
- Inhaled Treprostinil in Group-3 Pulmonary HypertensionThe Journal of Heart and Lung Transplantation, 2015
- Pulmonary Hypertension due to Lung Disease and/or HypoxiaClinics in Chest Medicine, 2013
- Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonistBiochemical Pharmacology, 2012
- Six-Minute-Walk Test in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial HypertensionJournal of the American College of Cardiology, 2010
- Iloprost Improves Gas Exchange and Exercise Tolerance in Patients with Pulmonary Hypertension and Chronic Obstructive Pulmonary DiseaseRespiration, 2009
- Pulmonary hypertension in interstitial lung diseaseInternational Journal of Clinical Practice, 2008
- The distance-saturation product predicts mortality in idiopathic pulmonary fibrosisRespiratory Medicine, 2006